Travocort

Package Leaflet: Information for the User

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Travocort

(10 mg + 1 mg)/g (1 + 0.1% w/w), cream
Isoconazole nitrate + Diflucortolone valerate

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

• Keep this leaflet, so you can read it again if you need to.
• If you have any doubts, consult your doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of Contents of the Leaflet

• 1. What is Travocort and what is it used for
• 2. Important information before using Travocort
• 3. How to use Travocort
• 4. Possible side effects
• 5. How to store Travocort
• 6. Contents of the pack and other information

1. What is Travocort and what is it used for

The medicine contains two active substances: isoconazole nitrate and diflucortolone valerate. Isoconazole nitrate treats fungal skin diseases.
Diflucortolone valerate belongs to a group of corticosteroids with strong effects, reduces skin inflammation, and alleviates symptoms such as itching, burning, and pain.
Travocort is indicated for the initial treatment of superficial fungal skin infections with concomitant severe inflammatory or eczematous skin changes, e.g., hands, interdigital spaces of the feet, and groin and genital areas.

2. Important information before using Travocort

When not to use Travocort:

• if the patient is allergic (hypersensitive) to isoconazole nitrate and diflucortolone valerate or any of the other ingredients of this medicine (listed in section 6),
• on syphilitic or tubercular lesions,
• on lesions caused by viral skin diseases (e.g., chickenpox, shingles, herpes),
• on lesions caused by rosacea, acne, or seborrheic dermatitis.

Warnings and precautions

Before starting treatment with Travocort, discuss it with your doctor or pharmacist.

• In the case of concomitant bacterial infection, the doctor will use antibacterial treatment.
• Avoid contact of the medicine with the eyes and mucous membranes. If the medicine gets into the eyes, rinse them thoroughly with water.

Apply the medicine carefully to avoid getting it into the eyes or on the mucous membranes.

• Using the medicine on large areas of skin or for a long time, especially under occlusive dressings, increases the risk of systemic side effects.
• If the patient has glaucoma, they should inform their doctor. During treatment with Travocort, there is a risk of developing glaucoma if the medicine is used under dressings, on large areas of skin, for a long time, or if the medicine is applied to the skin near the eyes.
• If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.
• If Travocort is used in the genital area, some of its ingredients may damage latex condoms and diaphragms. Therefore, they may not be effective as mechanical contraceptives or as a means of preventing sexually transmitted diseases. For more information, consult your doctor or pharmacist.
• The medicine should be used with caution and for a short time on the skin of the face and in children. Children are at greater risk of systemic effects of topical corticosteroids than adults.
• Hygiene is essential during treatment with Travocort. To prevent relapse, you should:
• change your personal underwear, bedding, and towels (preferably cotton) daily and wash them in very hot water or boil them,
• dry the areas between the toes well after washing,
• change your socks or tights daily and wash them in very hot water or boil them.

Travocort and other medicines

Tell your doctor or pharmacist about all medicines you are taking or have recently taken, as well as any medicines you plan to take.
No studies have been conducted on the interaction of Travocort with other medicines.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before using this medicine. The doctor will carefully assess whether the benefits to the mother outweigh the potential risk to the fetus.
Pregnancy
Do not use Travocort in the first trimester of pregnancy. The decision to use the medicine in the remaining period of pregnancy is made by the doctor, taking into account the benefit-risk ratio. During pregnancy, avoid using the medicine on large areas of skin, for a long time, or under dressings.
Breastfeeding
It is not known whether Travocort passes into breast milk, but it cannot be ruled out that it may pose a risk to the health of the breastfed child.
During breastfeeding, avoid using Travocort:

• on the breast skin,
• under dressings or on large areas of skin,
• for a long time.

Fertility
There are no data on the negative effect of Travocort on fertility.

Driving and using machines

It is unlikely that Travocort will affect your ability to drive or use machines.

Travocort contains a small amount of cetostearyl alcohol.

Travocort contains cetostearyl alcohol, which may cause skin reactions (e.g., contact dermatitis).

3. How to use Travocort

Always use this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.

Dosage

Apply a thin layer of Travocort to the affected skin area twice a day.
Treatment with Travocort should be stopped when the skin condition improves. Usually, treatment should not last longer than two weeks. If necessary, the doctor may continue treatment with an antifungal medicine that does not contain a corticosteroid, especially when using the medicine in the groin and external genital areas.
Hygiene is essential during treatment with Travocort (see section 2).

Use in children and adolescents

No dose adjustment is necessary for children from 2 years of age and adolescents. Do not use in children under 2 years of age.

Using more than the recommended dose of Travocort

It is unlikely that Travocort will cause acute poisoning after a single application of too much medicine or accidental ingestion of the medicine.

Missing a dose of Travocort

Do not take a double dose to make up for a missed dose.
Take the next dose at the right time and continue treatment as prescribed.
If you have any further doubts about using the medicine, consult your doctor or pharmacist.

4. Possible side effects

Like all medicines, Travocort can cause side effects, although not everybody gets them.
The following side effects, observed in clinical trials, are presented according to their frequency:

Common(affect more than 1 in 10 people)

• skin irritation or burning sensation at the application site.

Uncommon(affect more than 1 in 100 people)

• redness, dryness at the application site,
• skin stretch marks.

Unknown(frequency cannot be estimated from available data)

• itching or blisters at the application site,
• blurred vision.

Additionally, as with the use of other topical corticosteroids, the following side effects may occur (frequency unknown):
skin thinning (atrophy), folliculitis at the application site, excessive body hair growth, superficial vessel dilation (telangiectasia), perioral dermatitis, skin discoloration, acne-like changes, and (or) skin allergic reactions to any of the ingredients of Travocort. Systemic side effects may occur because the ingredients of the medicine can penetrate the skin.
It cannot be ruled out that side effects may occur in newborns whose mothers used the medicine for a long time during pregnancy or breastfeeding, or used it on large areas of skin.

Reporting side effects

If you experience any side effects, including any side effects not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder or parallel importer.
Reporting side effects will help gather more information on the safety of the medicine.

5. How to store Travocort

Keep out of the sight and reach of children.
Do not store above 30°C.
Do not use Travocort after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

What Travocort contains

• The active substances are isoconazole nitrate and diflucortolone valerate. 1 g of cream contains 10 mg (1% w/w) of isoconazole nitrate and 1 mg (0.1% w/w) of diflucortolone valerate.
• The other ingredients are white petrolatum, liquid paraffin, cetostearyl alcohol, polysorbate 60, sorbitan stearate, disodium edetate, and purified water.

What Travocort looks like and contents of the pack

Travocort is a white-yellow, opaque cream.
The packaging of the medicine is an aluminum tube with an HDPE cap, containing 15 g of cream, placed in a cardboard box.
For more information, consult the marketing authorization holder or parallel importer.

Marketing authorization holder in Ireland, the country of export:

LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Denmark

Manufacturer:

LEO Pharma Manufacturing Italy S.r.l.
Via E. Schering 21
20054 Segrate (MI)
Italy

Parallel importer:

Allpharm Sp. z o.o. sp.k.
ul. M. Zdziechowskiego 11/4
02-659 Warsaw

Repackaged by:

CEFEA Sp. z o.o. Sp.
komandytowa
ul. Działkowa 56
02-234 Warsaw
Synoptis Industrial Sp. z o.o.
ul. Forteczna 35-37
87-100 Toruń
Shiraz Productions Sp. z o.o.
ul. Tymiankowa 24/28
95-054 Ksawerów
Marketing authorization number in Ireland, the country of export:PA 1025/12/1

Parallel import authorization number: 200/25

Date of leaflet approval: 09.06.2025

[Information about the trademark]